title: Effects of conversion from sirolimus oral solution to tablets in stable Taiwanese renal transplant recipients.
abstract: OBJECTIVE
  Sirolimus (SRL) has a considerable inter- and intra- individual variability in clearance. Steady-state trough concentration (C(0)) is a reliable index of SRL exposure. This study assessed the effect of conversion of SRL oral solution to tablet form on C(0) in stable renal transplant recipients.
  
  
  METHODS
  Twenty two stable renal transplant recipients who had received calcineurin inhibitor (CNI)/SRL solution/ steroid for more than 3 months before conversion from SRL solution to tablets were included. C(0) values of SRL were compared for the periods of use of each dosage form. The relation between liver function and SRL levels was also assessed.
  
  
  RESULTS
  With a dose of 0.03 mg/kg/day, SRL solution and tablets achieved a similar dose-adjusted C(0) (mean +/- SEM, 2.9 +/- 0.3 ng/mL/mg) upon conversion. Similar results were found when multiple SRL C(0) values from different dosage form periods were compared. Four patients with persistent liver enzyme elevation had significantly higher dose-adjusted SRL C(0) values with both the solution (mean +/- SEM, 4.5 +/- 0.7 vs 2.3 +/- 0.1 ng/mL/mg; p < 0.01) and the tablet formulation (4.0 +/- 0.5 vs 2.6 +/- 0.2 ng/mL/mg; p < 0.05).
  
  
  CONCLUSIONS
  Conversion from SRL solution to SRL tablets did not significantly affect the dose-adjusted SRL C(0). The dose-adjusted C(0) of SRL in patients with persistent liver enzyme elevation was significantly higher than in those with normal liver function.
authors.affiliation: School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
authors.forename: Fe-Lin Lin
authors.initials: FL
authors.lastname: Wu
authors.forename: Meng-Kun
authors.initials: MK
authors.lastname: Tsai
authors.forename: Shao-Wen
authors.initials: SW
authors.lastname: Sun
authors.forename: Russel Rhei-Long
authors.initials: RR
authors.lastname: Chen
authors.forename: Jin-Ding
authors.initials: JD
authors.lastname: Huang
authors.forename: Po-Huang
authors.initials: PH
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D008099:Liver / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012996:Solutions; D013607:Tablets
chemical_list: D007166:Immunosuppressive Agents; D012996:Solutions; D013607:Tablets; D020123:Sirolimus